S&P 500   3,254.69 (+0.55%)
DOW   26,884.71 (+0.45%)
QQQ   265.87 (+0.65%)
AAPL   108.81 (+1.58%)
MSFT   204.11 (+1.75%)
FB   249.39 (+0.15%)
GOOGL   1,418.54 (+0.65%)
AMZN   3,036.00 (+1.20%)
NVDA   496.50 (+2.38%)
TSLA   388.30 (+2.09%)
BABA   269.24 (-1.36%)
CGC   14.50 (-0.68%)
GE   6.10 (-0.16%)
MU   49.63 (-0.44%)
AMD   75.98 (+1.67%)
T   28.02 (+0.54%)
F   6.61 (-0.45%)
ACB   5.23 (+1.16%)
GILD   62.40 (-1.09%)
NFLX   471.56 (+0.20%)
DIS   122.41 (-0.71%)
BAC   23.53 (+1.16%)
BA   146.10 (-3.36%)
S&P 500   3,254.69 (+0.55%)
DOW   26,884.71 (+0.45%)
QQQ   265.87 (+0.65%)
AAPL   108.81 (+1.58%)
MSFT   204.11 (+1.75%)
FB   249.39 (+0.15%)
GOOGL   1,418.54 (+0.65%)
AMZN   3,036.00 (+1.20%)
NVDA   496.50 (+2.38%)
TSLA   388.30 (+2.09%)
BABA   269.24 (-1.36%)
CGC   14.50 (-0.68%)
GE   6.10 (-0.16%)
MU   49.63 (-0.44%)
AMD   75.98 (+1.67%)
T   28.02 (+0.54%)
F   6.61 (-0.45%)
ACB   5.23 (+1.16%)
GILD   62.40 (-1.09%)
NFLX   471.56 (+0.20%)
DIS   122.41 (-0.71%)
BAC   23.53 (+1.16%)
BA   146.10 (-3.36%)
S&P 500   3,254.69 (+0.55%)
DOW   26,884.71 (+0.45%)
QQQ   265.87 (+0.65%)
AAPL   108.81 (+1.58%)
MSFT   204.11 (+1.75%)
FB   249.39 (+0.15%)
GOOGL   1,418.54 (+0.65%)
AMZN   3,036.00 (+1.20%)
NVDA   496.50 (+2.38%)
TSLA   388.30 (+2.09%)
BABA   269.24 (-1.36%)
CGC   14.50 (-0.68%)
GE   6.10 (-0.16%)
MU   49.63 (-0.44%)
AMD   75.98 (+1.67%)
T   28.02 (+0.54%)
F   6.61 (-0.45%)
ACB   5.23 (+1.16%)
GILD   62.40 (-1.09%)
NFLX   471.56 (+0.20%)
DIS   122.41 (-0.71%)
BAC   23.53 (+1.16%)
BA   146.10 (-3.36%)
S&P 500   3,254.69 (+0.55%)
DOW   26,884.71 (+0.45%)
QQQ   265.87 (+0.65%)
AAPL   108.81 (+1.58%)
MSFT   204.11 (+1.75%)
FB   249.39 (+0.15%)
GOOGL   1,418.54 (+0.65%)
AMZN   3,036.00 (+1.20%)
NVDA   496.50 (+2.38%)
TSLA   388.30 (+2.09%)
BABA   269.24 (-1.36%)
CGC   14.50 (-0.68%)
GE   6.10 (-0.16%)
MU   49.63 (-0.44%)
AMD   75.98 (+1.67%)
T   28.02 (+0.54%)
F   6.61 (-0.45%)
ACB   5.23 (+1.16%)
GILD   62.40 (-1.09%)
NFLX   471.56 (+0.20%)
DIS   122.41 (-0.71%)
BAC   23.53 (+1.16%)
BA   146.10 (-3.36%)
Log in
NASDAQ:JNCE

Jounce Therapeutics Competitors

$7.80
-0.16 (-2.01 %)
(As of 09/24/2020 12:18 PM ET)
Add
Compare
Today's Range
$7.24
Now: $7.80
$7.92
50-Day Range
$4.57
MA: $6.35
$10.95
52-Week Range
$2.79
Now: $7.80
$11.72
Volume24,813 shs
Average Volume646,444 shs
Market Capitalization$265.73 million
P/E Ratio12.58
Dividend YieldN/A
Beta2.11

Competitors

Jounce Therapeutics (NASDAQ:JNCE) Vs. RGNX, ATRA, BDTX, ADVM, TBIO, and ALEC

Should you be buying JNCE stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Jounce Therapeutics, including Regenxbio (RGNX), Atara Biotherapeutics (ATRA), I-Mab (BDTX), Adverum Biotechnologies (ADVM), Translate Bio (TBIO), and Alector (ALEC).

Regenxbio (NASDAQ:RGNX) and Jounce Therapeutics (NASDAQ:JNCE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.

Profitability

This table compares Regenxbio and Jounce Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regenxbio-222.24%-31.06%-28.08%
Jounce TherapeuticsN/A13.49%11.31%

Institutional & Insider Ownership

77.5% of Regenxbio shares are held by institutional investors. Comparatively, 74.1% of Jounce Therapeutics shares are held by institutional investors. 14.1% of Regenxbio shares are held by insiders. Comparatively, 44.0% of Jounce Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Regenxbio has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Jounce Therapeutics has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Regenxbio and Jounce Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regenxbio01602.86
Jounce Therapeutics11302.40

Regenxbio currently has a consensus target price of $66.00, indicating a potential upside of 143.09%. Jounce Therapeutics has a consensus target price of $16.3333, indicating a potential upside of 109.40%. Given Regenxbio's stronger consensus rating and higher possible upside, equities analysts plainly believe Regenxbio is more favorable than Jounce Therapeutics.

Earnings & Valuation

This table compares Regenxbio and Jounce Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regenxbio$35.23 million28.77$-94,730,000.00($3.26)-8.33
Jounce Therapeutics$147.87 million1.80$56.82 million$1.664.70

Jounce Therapeutics has higher revenue and earnings than Regenxbio. Regenxbio is trading at a lower price-to-earnings ratio than Jounce Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Jounce Therapeutics beats Regenxbio on 9 of the 14 factors compared between the two stocks.

Jounce Therapeutics (NASDAQ:JNCE) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Jounce Therapeutics and Atara Biotherapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jounce Therapeutics11302.40
Atara Biotherapeutics11802.70

Jounce Therapeutics presently has a consensus price target of $16.3333, indicating a potential upside of 109.40%. Atara Biotherapeutics has a consensus price target of $30.8571, indicating a potential upside of 137.36%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than Jounce Therapeutics.

Risk and Volatility

Jounce Therapeutics has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500.

Valuation & Earnings

This table compares Jounce Therapeutics and Atara Biotherapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jounce Therapeutics$147.87 million1.80$56.82 million$1.664.70
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-2.29

Jounce Therapeutics has higher revenue and earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Jounce Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Jounce Therapeutics and Atara Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jounce TherapeuticsN/A13.49%11.31%
Atara BiotherapeuticsN/A-96.77%-83.82%

Institutional and Insider Ownership

74.1% of Jounce Therapeutics shares are owned by institutional investors. 44.0% of Jounce Therapeutics shares are owned by insiders. Comparatively, 4.3% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Jounce Therapeutics beats Atara Biotherapeutics on 8 of the 12 factors compared between the two stocks.

I-Mab (NASDAQ:BDTX) and Jounce Therapeutics (NASDAQ:JNCE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings for I-Mab and Jounce Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
I-Mab00503.00
Jounce Therapeutics11302.40

I-Mab presently has a consensus target price of $48.00, indicating a potential upside of 82.37%. Jounce Therapeutics has a consensus target price of $16.3333, indicating a potential upside of 109.40%. Given Jounce Therapeutics' higher probable upside, analysts plainly believe Jounce Therapeutics is more favorable than I-Mab.

Profitability

This table compares I-Mab and Jounce Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
I-MabN/AN/AN/A
Jounce TherapeuticsN/A13.49%11.31%

Institutional & Insider Ownership

64.4% of I-Mab shares are owned by institutional investors. Comparatively, 74.1% of Jounce Therapeutics shares are owned by institutional investors. 44.0% of Jounce Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares I-Mab and Jounce Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
I-MabN/AN/A$-35,260,000.00($16.99)-1.55
Jounce Therapeutics$147.87 million1.80$56.82 million$1.664.70

Jounce Therapeutics has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Jounce Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Jounce Therapeutics beats I-Mab on 9 of the 11 factors compared between the two stocks.

Adverum Biotechnologies (NASDAQ:ADVM) and Jounce Therapeutics (NASDAQ:JNCE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares Adverum Biotechnologies and Jounce Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$250,000.003,510.32$-64,490,000.00($1.01)-10.77
Jounce Therapeutics$147.87 million1.80$56.82 million$1.664.70

Jounce Therapeutics has higher revenue and earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Jounce Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Adverum Biotechnologies and Jounce Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adverum BiotechnologiesN/A-37.66%-31.46%
Jounce TherapeuticsN/A13.49%11.31%

Analyst Ratings

This is a summary of current recommendations for Adverum Biotechnologies and Jounce Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adverum Biotechnologies01802.89
Jounce Therapeutics11302.40

Adverum Biotechnologies currently has a consensus target price of $24.3750, suggesting a potential upside of 124.03%. Jounce Therapeutics has a consensus target price of $16.3333, suggesting a potential upside of 109.40%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, research analysts plainly believe Adverum Biotechnologies is more favorable than Jounce Therapeutics.

Volatility and Risk

Adverum Biotechnologies has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Jounce Therapeutics has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500.

Institutional & Insider Ownership

74.1% of Jounce Therapeutics shares are owned by institutional investors. 4.2% of Adverum Biotechnologies shares are owned by company insiders. Comparatively, 44.0% of Jounce Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Jounce Therapeutics beats Adverum Biotechnologies on 9 of the 13 factors compared between the two stocks.

Translate Bio (NASDAQ:TBIO) and Jounce Therapeutics (NASDAQ:JNCE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Profitability

This table compares Translate Bio and Jounce Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Translate Bio-393.56%-54.90%-28.46%
Jounce TherapeuticsN/A13.49%11.31%

Institutional and Insider Ownership

89.0% of Translate Bio shares are held by institutional investors. Comparatively, 74.1% of Jounce Therapeutics shares are held by institutional investors. 12.3% of Translate Bio shares are held by company insiders. Comparatively, 44.0% of Jounce Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Translate Bio and Jounce Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Translate Bio00703.00
Jounce Therapeutics11302.40

Translate Bio presently has a consensus target price of $32.50, suggesting a potential upside of 153.31%. Jounce Therapeutics has a consensus target price of $16.3333, suggesting a potential upside of 109.40%. Given Translate Bio's stronger consensus rating and higher possible upside, analysts plainly believe Translate Bio is more favorable than Jounce Therapeutics.

Volatility and Risk

Translate Bio has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Jounce Therapeutics has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500.

Earnings and Valuation

This table compares Translate Bio and Jounce Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Translate Bio$7.80 million122.12$-113,290,000.00($1.84)-6.97
Jounce Therapeutics$147.87 million1.80$56.82 million$1.664.70

Jounce Therapeutics has higher revenue and earnings than Translate Bio. Translate Bio is trading at a lower price-to-earnings ratio than Jounce Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Jounce Therapeutics beats Translate Bio on 9 of the 14 factors compared between the two stocks.

Jounce Therapeutics (NASDAQ:JNCE) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.

Profitability

This table compares Jounce Therapeutics and Alector's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jounce TherapeuticsN/A13.49%11.31%
Alector-775.34%-50.88%-28.63%

Institutional and Insider Ownership

74.1% of Jounce Therapeutics shares are held by institutional investors. Comparatively, 63.0% of Alector shares are held by institutional investors. 44.0% of Jounce Therapeutics shares are held by insiders. Comparatively, 13.9% of Alector shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Jounce Therapeutics and Alector, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jounce Therapeutics11302.40
Alector00803.00

Jounce Therapeutics presently has a consensus price target of $16.3333, suggesting a potential upside of 109.40%. Alector has a consensus price target of $32.80, suggesting a potential upside of 188.99%. Given Alector's stronger consensus rating and higher possible upside, analysts clearly believe Alector is more favorable than Jounce Therapeutics.

Risk and Volatility

Jounce Therapeutics has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Valuation & Earnings

This table compares Jounce Therapeutics and Alector's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jounce Therapeutics$147.87 million1.80$56.82 million$1.664.70
Alector$21.22 million42.39$-105,390,000.00($1.71)-6.64

Jounce Therapeutics has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Jounce Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Jounce Therapeutics beats Alector on 10 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Regenxbio logo
RGNX
Regenxbio
1.6$27.15-5.1%$1.07 billion$35.23 million-7.44Analyst Report
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$13.00-3.2%$1.05 billionN/A-2.59Analyst Report
BDTX
I-Mab
1.5$26.32-0.6%$985.09 millionN/A-1.55
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.4$10.88-3.6%$957.39 million$250,000.00-8.99
TBIO
Translate Bio
1.4$12.83-3.1%$922.85 million$7.80 million-7.50
ALEC
Alector
1.4$11.35-1.1%$889.30 million$21.22 million-5.59
Replimune Group logo
REPL
Replimune Group
1.5$21.41-0.4%$866.19 millionN/A-12.90
Vericel logo
VCEL
Vericel
1.7$18.17-0.4%$818.57 million$117.85 million-1,817.00Analyst Report
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.4$41.56-0.7%$811.53 millionN/A-33.52
Cellectis logo
CLLS
Cellectis
1.3$17.61-6.7%$811.09 million$22.99 million-11.36
Agenus logo
AGEN
Agenus
1.5$4.08-5.1%$786.96 million$150.05 million-3.58Analyst Report
Vaxart logo
VXRT
Vaxart
1.5$7.13-0.8%$785.16 million$9.86 million-12.08
Nantkwest logo
NK
Nantkwest
2.0$7.03-0.4%$755.79 million$40,000.00-9.90
TCRR
Tcr2 Therapeutics
1.6$18.20-3.7%$629.20 millionN/A-7.46
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
2.1$3.45-1.4%$618.00 million$48.83 million-4.11
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.4$12.60-0.7%$598.27 million$2.91 million-4.57Analyst Report
PASG
Passage Bio
1.6$12.86-3.6%$563.81 millionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.6$11.65-0.2%$563.29 million$69.89 million-2.64
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.59-3.6%$555.25 millionN/A-9.16Analyst Report
Avrobio logo
AVRO
Avrobio
1.6$13.38-1.0%$539.72 millionN/A-4.68
Scholar Rock logo
SRRK
Scholar Rock
1.4$17.28-3.1%$532.37 million$20.49 million-7.96
ORTX
Orchard Therapeutics
1.5$4.60-5.7%$472.70 million$2.51 million-2.51
BVXV
BIONDVAX PHARMA/S
0.5$39.49-0.3%$467.77 millionN/A-13.08
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.4$13.99-0.1%$459.99 millionN/A-12.06
MeiraGTx logo
MGTX
MeiraGTx
1.5$12.09-1.7%$459.19 million$13.29 million-7.85
OYST
Oyster Point Pharma
1.6$18.15-1.8%$459.18 millionN/A-1.66
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.4$11.69-1.2%$432.33 million$104.39 million-7.13
HARP
Harpoon Therapeutics
1.5$15.53-2.1%$398.75 million$5.78 million-6.90
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$4.59-3.5%$383.64 millionN/A-2.07
Proteon Therapeutics logo
PRTO
Proteon Therapeutics
0.8$17.01-0.8%$377.27 millionN/A-14.79
PRVL
Prevail Therapeutics
1.7$10.72-2.6%$376.37 millionN/A-4.52Analyst Report
Sutro Biopharma logo
STRO
Sutro Biopharma
1.4$10.48-1.2%$371.35 million$42.74 million-9.53Insider Selling
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.7$18.31-0.4%$361.45 million$340,000.00-6.61
PDL BioPharma logo
PDLI
PDL BioPharma
0.8$3.11-2.9%$344.23 million$54.76 million-2.34Ex-Dividend
IPHA
Innate Pharma
1.2$3.81-1.0%$291.63 million$96.12 million-11.21
DTIL
Precision BioSciences
1.6$5.99-12.9%$273.50 million$22.24 million-3.12
Eiger Biopharmaceuticals logo
EIGR
Eiger Biopharmaceuticals
2.0$9.40-0.9%$272.55 millionN/A-3.52Heavy News Reporting
CABA
Cabaletta Bio
1.4$9.66-0.9%$261.31 millionN/A-2.37Analyst Downgrade
Surface Oncology logo
SURF
Surface Oncology
1.4$5.96-1.3%$241.03 million$15.36 million-6.77
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
2.0$8.95-1.2%$231.53 million$20,000.000.00
DYAI
Dyadic International
1.3$7.18-0.6%$198.42 million$1.68 million-23.16
ADMA Biologics logo
ADMA
ADMA Biologics
2.2$2.07-2.4%$192.56 million$29.35 million-2.41
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.9$1.49-2.0%$190.87 million$4.13 million-3.63
DBV TECHNOLOGIE/S logo
DBVT
DBV TECHNOLOGIE/S
1.8$1.60-2.2%$179.06 million$14.75 million-0.68
AXLA
Axcella Health
1.6$4.26-0.7%$156.37 millionN/A-1.66
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$5.80-0.3%$150.21 millionN/A-8.66
GNFT
GENFIT S A/ADR
1.3$3.87-2.1%$146.23 million$45.88 million-1.96
INMB
INmune Bio
1.6$10.16-1.5%$138.65 millionN/A-11.42
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$4.79-1.9%$132.91 million$2.45 million-2.21
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.5$2.89-1.0%$130.60 million$20.92 million-2.31
This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.